nach oben

Erschienen in:

01.06.2003 | Original Research Article

Renewable Standard Reference Material for the Detection of TP53 Mutations

verfasst von: Catherine D. O’Connell, Lois A. Tully, Joseph M. Devaney, Michael A. Marino, John P. Jakupciak, Donald H. Atha

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 2/2003

Einloggen, um Zugang zu erhalten

Abstract

Background: Numerous DNA-based tests are currently in use or under development for the detection of mutations associated with disease. Most of the current methods use PCR amplification technologies and detection after separation or chromatography of the products. We have developed a panel of standard reference materials consisting of 12 plasmid clones containing a 2.0kb region of the TP53 gene, including exons 5–9. Eleven of these clones contain a single mutation within the mutational hot spots of the TP53 gene, the twelfth is wild-type in this region of the gene. The mutations are amino acid (aa) 128: C to T; aa 175: G to A; aa 237: T to C; aa 245: G to A; aa 248: C to T; aa 248: G to A; aa 249: G to T; aa 273: C to T; aa 273: G to A; aa 282: C to T; and aa 328: T to C. These standard reference materials (SRMs), created by site-directed mutagenesis of wild-type TP53 from a human cell line, include the specific mutations most commonly found to be associated with cancer. Their use will improve disease detection by serving as validation materials to monitor errors in measurement methods, including PCR amplification, amplicon separation, and data analysis from different technology platforms.

Methods and results: The single point mutations of the panel were validated by capillary electrophoresis single-strand conformational polymorphism analysis, denaturing gradient gel electrophoresis, and denaturing high-performance liquid chromatography, as well as full sequence analysis of both DNA strands of the cloned material. For both heteroduplex analysis methods, the presence of the mutations was resolved for each SRM.

Conclusion: The generation of a standard TP53 reference panel and demonstration that the panel can successfully validate mutation detection across different mutation scanning technology platforms. Hence, this panel functions as an SRM to normalize results obtained from different laboratories using different techniques.

The use of tradenames is for product identification purposes only and does not imply endorsement.

Eng C, Brody LC, Wagner TM, et al. Steering Committee of the Breast Cancer Information Core (BIC) Consortium. Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA 1. J Med Genet 2001; 38: 824–33

Kristensen VN, Kelefiotis D, Kristensen T, et al. High-throughput methods for detection of genetic variation. Biotechniques 2001; 30: 318–32PubMed

Ellis LA, Taylor CF, Taylor GR. A comparison of fluorescent SSCP and denaturing HPLC for high throughput mutation scanning. Hum Mutat 2000; 15: 556–64PubMedCrossRef

Cotton RGH. Mutation detection novel technologies, developments and applications for analysis of the humand genome. Hum Mutat 2002; 19: 313–4CrossRef

Cotton RGH. Slowly but surely towards better scanning for mutations. Trends Genet 1997; 13: 43–5PubMedCrossRef

Liu Q, Feng J, Buzin C, et al. Detection of virtually all mutations-SSCP (DOVAM-S): a rapid method for mutation scanning with virtually 100% sensitivity. Biotechniques 1999; 26: 932–42PubMed

O’Connell CD, Atha DH, Oldenburg MC, et al. Detection of p53 gene mutations: analysis by single strand conformation polymorphism and cleavase fragment length polymorphism. Electrophoresis 1999; 20: 1211–23PubMedCrossRef

O’Connel CD, Atha DH, Jakupciak JP, et al. Standardization of PCR Amplification for Fragile X Trinucleotide Repeat Measurements. Clin Genet 2002; 61: 13–20CrossRef

Hollstein M, Sidransky D, Vogelstein B, et al. P53 mutations in human cancer. Science 1991; 253: 49–53PubMedCrossRef

10.

Vogelstein B, Kinzer K. p53 function and dysfunction. Cell 1992; 70: 523–6PubMedCrossRef

11.

Somlo G, Simpson JF, Frankel P, et al. Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. Br J Cancer 2002; 87: 281–8PubMedCrossRef

12.

Liu MC, Gelmann EP. p53 gene mutations: case study of a clinical marker for solid tumors. Semin Oncol 2002; 29: 246–57PubMedCrossRef

13.

Hollstein M, Rice C, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucl Acids Res 1994; 22: 3551–5PubMed

14.

Cariello NF, Cui L, Beroud C, et al. Database and software for the analysis of mutations in the human p53 gene. Cancer Res 1994; 54: 4454–60PubMed

15.

Geisler S, Lonning PE, Aas T, et al. Influence of TP53 gene alterations and c-erb B-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61: 2505–12PubMed

16.

Mirza AN, Mirza NQ, Vlastos G, et al. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002; 235: 10–26PubMedCrossRef

17.

Genetests laboratory directory [online]. Available from URL: http://www.genetests.org [Accessed 2003 Oct 1]

18.

Barker PE, Watson MS, Ticehurst JR, et al. NIST physical standards for DNA-based medical testing. J Clin Lab Anal 2002; 16: 5–10PubMedCrossRef

19.

Atha DH, Wenz H-M, Morehead H, et al. Detection of p53 point mutations by single strand conformation polymorphism: analysis by capillary electrophoresis. Electrophoresis 1998; 19: 172–9PubMedCrossRef

20.

Orita M, Iwahana H, Kanazawa H, et al. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci U S A 1989; 86: 2766–70PubMedCrossRef

21.

Gelfi C, Righetti SC, Zunino F, et al. Detection of p53 point mutations by double-gradient, denaturing gradient gel electrophoresis. Electrophoresis 1997; 18: 2921–7PubMedCrossRef

22.

O’Donovan MC, Oefner PJ, Roberts SC, et al. Blind analysis of denaturing high performance liquid chromatography as a tool for mutation detection. Genomics 1998; 52: 44–9PubMedCrossRef

23.

Oefner PJ, Underhill PA. DNA mutation detection using denaturing high-performance liquid chromatography (DHPLC). In: Dracopoli NC, Haines JL, Korff BR, et al., editors. Current protocols in human genetics. Suppl 19. New York: John Wiley and Sons Inc., 1998: 7.10.1-7.10.12

24.

Holinski-Feder E, Muller-Koch Y, Friedl W, et al. DHPLC mutation analysis of the hereditary non-polypoisis colon cancer (HNPCC) genes hMLH1 and hMSH 2. J Biochem Biophys Methods 2001; 47: 21–32PubMedCrossRef

25.

Spiegelman JI, Mindrinos MN, Oefner PJ. High-accuracy DNA sequence variation screening by DHPLC. Biotechniques 2001; 29: 1084–92

26.

Keller G, Hartmann A, Mueller J, et al. Denaturing high pressure chromatography (DHPLC) for the analysis of somatic p53 mutations. Lab Invest 2001; 81: 1735–7PubMedCrossRef

27.

International Agency for Research in Cancer (IARC) TP53 mutation database [online]. Available from URL: http://www.iarc.fr/p53/ [Accessed 2003 Sep 4]

28.

Wenz H-M, Ramachandra S, O’Connell CD, et al. Identification of known p53 point mutations by capillary electrophoresis using unique mobility profiles in a blinded study. Mutat Res 1998; 382: 121–32CrossRef

29.

Greiner TC, Moynihan MJ, Chan WC, et al. p53 mutation in mantle cell lymphome are associated with variant cytology and predict a poor prognosis. Blood 1996; 87: 4302–10PubMed

30.

Gulberg P, Nedergaard T, Nielson HG, et al. Single step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat 1997; 9: 348–55CrossRef

31.

O’Connell CD, Tian J, Juhasz A, et al. Development of standard reference materials for diagnosis of p53 mutations: analysis by slab gel single strand conformation polymorphism. Electrophoresis 1998; 19: 164–71PubMedCrossRef

32.

Fodde R, Losekoot M. Mutation detection by denaturing gradient gel electrophoresis (DGGE). Hum Mutat 1994; 3: 83–94PubMedCrossRef

33.

Anderson TI, Borresen DAL. Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas: advantages of using constant denaturant gel electrophoresis in mutation detection. Diagn Mol Pathol 1995; 4: 203–11CrossRef

34.

Standards and guidelines for clinical genetics laboratories. 2nd ed. Bethesda (MD): American College of Medical Genetics, 1999

35.

Ahrendt SA, Halachmi S, Chow JT, et al. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci U S A 1999; 96: 7382–7PubMedCrossRef

Titel: Renewable Standard Reference Material for the Detection of TP53 Mutations
verfasst von: Catherine D. O’Connell
Lois A. Tully
Joseph M. Devaney
Michael A. Marino
John P. Jakupciak
Donald H. Atha
Publikationsdatum: 01.06.2003
Verlag: Springer International Publishing
Erschienen in: Molecular Diagnosis & Therapy / Ausgabe 2/2003
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI: https://doi.org/10.1007/BF03260024

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2003

Investigation into a Possible Association Between Oral Lichen Planus, the Human Herpesviruses, and the Human Papillomaviruses

Uniparental Disomy and Robertsonian Translocations

Endothelial Nitric Oxide Synthase Gene Intron 4 Polymorphism in Type 2 Diabetes Mellitus

Hyperekplexia (Startle Disease)

A Novel Mutation in Exon 5 of the Glucokinase Gene in an Argentinian Family with Maturity Onset Diabetes of the Young